 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 908 | 回復(fù): 8 | ||
| 當(dāng)前只顯示滿足指定條件的回帖，點(diǎn)擊這里查看本話題的所有回帖 | ||
tzkcarlos銀蟲 (小有名氣)
|
[求助]
自身免疫學(xué)翻譯為中文-幾段話，Autoimmunity Reviews 13 (2014) 108–113
|
|
|
PLA 2 R1 is a type 1 transmembrane receptor that is expressed by podocytes. Besides a short membrane-spanning intracellular domain, the receptor consists of a long extracellular domain with a cysteine-rich head, a fibronectin type II-like repeat domain and eight repeated carbohydrate-recognition domains [22]. PLA 2 R1 is one of four members of the mannose receptor family [23]. All of them have a conserved domain structure and share common characteristics such as constitutive endocytic recycling at the plasma membrane [24] which may provide a constant source of accessible PLA 2 R1 at the podocyte membrane for immune-complex formation [23]. Further more, the receptors exist in both an extended and a bent conformation conferring distinct ligand binding and oligomerization capacities [25]. Since the anti-PLA 2 R1 autoantibodies in patients with pMN only recognize a conformation-dependent target epitope [21], it is assumed that autoantibody-binding might only occur in one of these two configurations. Therefore, pMN might represent an autoimmune conformational disease (‘conformeropathy’), such as Goodpasture syndrome [1]. Although the exact mechanisms causing pMN are still under investigation, different studies show a strong relationship between antibody levels to podocytic proteins and disease activity. Since the discovery of anti-PLA 2 R1 autoantibodies by Beck et al. in 2009, there has been strong evidence that they are a key player in the pathogenesis [21]. For example, autoantibodies to PLA 2 R1 can not only be eluted from kidney tissue of pMN patients, but also colocalize with PLA 2 R1 in the glomeruli [21]. Therefore, it is widely accepted that upon binding of circulating autoantibodies to PLA 2 R1 on podocytes, subepithelial deposits are formed in situ, leading to complement activation and a cascade of events subsequent to the nephrotic syndrome (in most of the cases) [37]. Interestingly, autoantibodies to PLA 2 R1 have shown to be mainly of the IgG4 subclass, which is regarded as being unable to activate the complement pathway [38,39]. Nevertheless, since the terminal complement compo- nent C5b-9 is detectable in glomeruli and urine of pMN patients [40,41], there is strong evidence for the involvement of the complement system. As most patients with MN have low or undetectable levels of C1q, the classical complement pathway can be excluded. Therefore, either the alternative or the lectin pathway seems to be predominantly involved [42]. This hypothesis is supported by the notion, that mannose binding lectin can be detected in glomeruli of MN patients [43]. |
回復(fù)此樓» 猜你喜歡
北科281學(xué)碩材料求調(diào)劑
已經(jīng)有6人回復(fù)
-
328求調(diào)劑，英語(yǔ)六級(jí)551，有科研經(jīng)歷
已經(jīng)有10人回復(fù)
-
298求調(diào)劑
已經(jīng)有6人回復(fù)
-
310求調(diào)劑
已經(jīng)有4人回復(fù)
-
311求調(diào)劑
已經(jīng)有6人回復(fù)
-
307求調(diào)劑
已經(jīng)有11人回復(fù)
-
材料與化工085600，總分304，本科有兩篇sci參與，求調(diào)劑
已經(jīng)有5人回復(fù)
-
315分，誠(chéng)求調(diào)劑，材料與化工085600
已經(jīng)有3人回復(fù)
-
求調(diào)劑一志愿海大，0703化學(xué)學(xué)碩304分，有大創(chuàng)項(xiàng)目，四級(jí)已過
已經(jīng)有10人回復(fù)
-
招08考數(shù)學(xué)
已經(jīng)有8人回復(fù)
tzkcarlos
銀蟲 (小有名氣)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 163.3
- 帖子: 72
- 在線: 18.3小時(shí)
- 蟲號(hào): 783503
- 注冊(cè): 2009-05-31
- 專業(yè): 化學(xué)計(jì)量學(xué)與化學(xué)信息學(xué)
3樓2014-08-25 23:21:23
ssssllllnnnn 
至尊木蟲 (知名作家)
Translator and Proofreader
- 翻譯EPI: 1690
- 應(yīng)助: 452 (碩士)
- 金幣: 31580.9
- 紅花: 100
- 帖子: 7681
- 在線: 19966.6小時(shí)
- 蟲號(hào): 3328089
- 注冊(cè): 2014-07-17
- 專業(yè): 腫瘤發(fā)生
【答案】應(yīng)助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
RXMCDM: 金幣+1, 多謝應(yīng)助！ 2014-08-26 00:17:29
tzkcarlos(phu_grassman代發(fā)): 金幣+30, he deserves it. Thanks for your cooperation. 2014-08-26 09:53:38
RXMCDM: 金幣+1, 多謝應(yīng)助！ 2014-08-26 00:17:29
tzkcarlos(phu_grassman代發(fā)): 金幣+30, he deserves it. Thanks for your cooperation. 2014-08-26 09:53:38
本樓樓主要求刪除 我覺得他花了不少時(shí)間和心思的，樓主卻一再挑剔，有點(diǎn)過分哦。  英文這種東西畢竟不是咱中國(guó)人的，翻譯過來(lái)難免變味，我們理工科的學(xué)生也不是學(xué)文學(xué)的，要達(dá)到“信、達(dá)、雅”也有點(diǎn)難哦。 樓主為何不參照應(yīng)助者提供的信息自己修飾一下呢？  |
2樓2014-08-25 22:24:21
ssssllllnnnn
至尊木蟲 (知名作家)
Translator and Proofreader
- 翻譯EPI: 1690
- 應(yīng)助: 452 (碩士)
- 金幣: 31580.9
- 紅花: 100
- 帖子: 7681
- 在線: 19966.6小時(shí)
- 蟲號(hào): 3328089
- 注冊(cè): 2014-07-17
- 專業(yè): 腫瘤發(fā)生
4樓2014-08-25 23:36:10
tzkcarlos
銀蟲 (小有名氣)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 163.3
- 帖子: 72
- 在線: 18.3小時(shí)
- 蟲號(hào): 783503
- 注冊(cè): 2009-05-31
- 專業(yè): 化學(xué)計(jì)量學(xué)與化學(xué)信息學(xué)
6樓2014-08-25 23:50:26
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 298求調(diào)劑 +6 | 上岸6666@ 2026-03-20 | 6/300 |
|
|---|---|---|---|---|
|
|
[考研] 275求調(diào)劑 +6 | shansx 2026-03-22 | 8/400 |
|
|
|
[考研]
 一志愿070300浙大化學(xué)358分，求調(diào)劑！
+3
|
酥酥魚.. 2026-03-21 | 3/150 |
|
|
[考研] 廣西大學(xué)材料導(dǎo)師推薦 +3 | 夏夏夏小正 2026-03-17 | 5/250 |
|
|
|
[考研] 0703化學(xué)調(diào)劑 +4 | 妮妮ninicgb 2026-03-21 | 4/200 |
|
|
|
[考研] 求調(diào)劑 +3 | 13341 2026-03-20 | 3/150 |
|
|
|
[考研] 材料工程（專）一志愿985 初試335求調(diào)劑 +3 | hiloiy 2026-03-17 | 4/200 |
|
|
|
[考研] 332求調(diào)劑 +4 | ydfyh 2026-03-17 | 4/200 |
|
|
|
[考研] 265求調(diào)劑 +9 | 梁梁校校 2026-03-17 | 9/450 |
|
|
|
[考研] 304求調(diào)劑 +6 | 曼殊2266 2026-03-18 | 6/300 |
|
|
|
[考研] 一志愿西南交大，求調(diào)劑 +5 | 材化逐夢(mèng)人 2026-03-18 | 5/250 |
|
|
|
[考研] 一志愿武漢理工材料工程專碩調(diào)劑 +9 | Doleres 2026-03-19 | 9/450 |
|
|
|
[考研] 材料學(xué)求調(diào)劑 +4 | Stella_Yao 2026-03-20 | 4/200 |
|
|
|
[考研] 0856調(diào)劑，是學(xué)校就去 +8 | sllhht 2026-03-19 | 9/450 |
|
|
|
[考研] 求調(diào)劑 +3 | 暗涌afhb 2026-03-16 | 3/150 |
|
|
|
[考研]
 320求調(diào)劑0856
+3
|
不想起名字112 2026-03-19 | 3/150 |
|
|
|
[考研] 085600材料與化工調(diào)劑 324分 +10 | llllkkkhh 2026-03-18 | 12/600 |
|
|
|
[考研] 328求調(diào)劑，英語(yǔ)六級(jí)551，有科研經(jīng)歷 +4 | 生物工程調(diào)劑 2026-03-16 | 12/600 |
|
|
|
[考研] 0703化學(xué)調(diào)劑 +3 | 妮妮ninicgb 2026-03-17 | 3/150 |
|
|
|
[考研] 070300化學(xué)學(xué)碩求調(diào)劑 +6 | 太想進(jìn)步了0608 2026-03-16 | 6/300 |
|